150 related articles for article (PubMed ID: 38296033)
1. Dialing for doctors: Secret shopper study of Arizona methadone and buprenorphine providers, 2022.
Meyerson BE; Treiber D; Brady BR; Newgass K; Bondurant K; Bentele KG; Samorano S; Arredondo C; Stavros N
J Subst Use Addict Treat; 2024 May; 160():209306. PubMed ID: 38296033
[TBL] [Abstract][Full Text] [Related]
2. Treatment access for opioid use disorder among women with medicaid in Florida.
Elmore AL; Patrick SW; McNeer E; Fryer K; Reid CN; Sappenfield WM; Mehra S; Salemi JL; Marshall J
Drug Alcohol Depend; 2023 May; 246():109854. PubMed ID: 37001322
[TBL] [Abstract][Full Text] [Related]
3. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
4. Consumer access to buprenorphine and methadone in certified community behavioral health centers: A secret shopper study.
Presnall NJ; Butler GC; Grucza RA
J Subst Abuse Treat; 2022 Aug; 139():108788. PubMed ID: 35534359
[TBL] [Abstract][Full Text] [Related]
5. Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.
Patrick SW; Buntin MB; Martin PR; Scott TA; Dupont W; Richards M; Cooper WO
Subst Abus; 2019; 40(3):356-362. PubMed ID: 29949454
[No Abstract] [Full Text] [Related]
6. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
7. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
[TBL] [Abstract][Full Text] [Related]
8. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
[TBL] [Abstract][Full Text] [Related]
9. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
[TBL] [Abstract][Full Text] [Related]
10. Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
Pasman E; Lee G; Kollin R; Rodriguez B; Agius E; Madden EF; Resko SM
Subst Use Misuse; 2022; 57(12):1828-1836. PubMed ID: 36041008
[No Abstract] [Full Text] [Related]
11. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
12. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
14. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
15. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
[TBL] [Abstract][Full Text] [Related]
16. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
17. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
[TBL] [Abstract][Full Text] [Related]
18. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.
Huhn AS; Hobelmann JG; Strickland JC; Oyler GA; Bergeria CL; Umbricht A; Dunn KE
JAMA Netw Open; 2020 Feb; 3(2):e1920843. PubMed ID: 32031650
[TBL] [Abstract][Full Text] [Related]
19. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
[TBL] [Abstract][Full Text] [Related]
20. Barriers to accessing opioid agonist therapy in pregnancy.
Bedrick BS; O'Donnell C; Marx CM; Friedman H; Carter EB; Stout MJ; Kelly JC
Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100225. PubMed ID: 33345932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
